HAEM5:Kikuchi-Fujimoto disease: Difference between revisions
No edit summary |
No edit summary |
||
| Line 39: | Line 39: | ||
==Gene Rearrangements== | ==Gene Rearrangements== | ||
<big>Kikuchi-Fujimoto disease does | <big>Kikuchi-Fujimoto disease does not have characteristic or recurrent genetic alterations.</big> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| Line 58: | Line 58: | ||
|} | |} | ||
==Individual Region Genomic Gain/Loss/LOH== | ==Individual Region Genomic Gain/Loss/LOH== | ||
<big>Kikuchi-Fujimoto disease does | <big>Kikuchi-Fujimoto disease does not have characteristic or recurrent genetic alterations.</big> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| Line 75: | Line 75: | ||
|} | |} | ||
==Characteristic Chromosomal or Other Global Mutational Patterns== | ==Characteristic Chromosomal or Other Global Mutational Patterns== | ||
<big>Kikuchi-Fujimoto disease does | <big>Kikuchi-Fujimoto disease does not have characteristic or recurrent genetic alterations.</big> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| Line 94: | Line 94: | ||
|} | |} | ||
==Gene Mutations (SNV/INDEL)== | ==Gene Mutations (SNV/INDEL)== | ||
<big>Kikuchi-Fujimoto disease does | <big>Kikuchi-Fujimoto disease does not have characteristic or recurrent genetic alterations.</big> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| Line 112: | Line 112: | ||
|} | |} | ||
==Epigenomic Alterations== | ==Epigenomic Alterations== | ||
N/A | |||
==Genes and Main Pathways Involved== | ==Genes and Main Pathways Involved== | ||
<big> | <big>While KFD does not have characteristic or recurrent genetic alterations, a</big> <big>study using exome and transcriptome sequencing of lymph node tissue samples from KFD patients found fourteen</big> <big>SNPs</big> <big>as possible candidate markers for the disease and hundreds of genes with altered expression involving immune system, chromatin remodeling, and transcription pathways.</big><ref>{{Cite journal|last=Anuntakarun|first=Songtham|last2=Larbcharoensub|first2=Noppadol|last3=Payungporn|first3=Sunchai|last4=Reamtong|first4=Onrapak|date=2021-06|title=Identification of genes associated with Kikuchi-Fujimoto disease using RNA and exome sequencing|url=https://pubmed.ncbi.nlm.nih.gov/33819568|journal=Molecular and Cellular Probes|volume=57|pages=101728|doi=10.1016/j.mcp.2021.101728|issn=1096-1194|pmid=33819568}}</ref> | ||
<big> | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| Line 129: | Line 127: | ||
==Familial Forms== | ==Familial Forms== | ||
<big>Some reports describe | <big>Some reports describe HLA class II associations (e.g., HLA-DPA1 and HLA-DPB1 polymorphisms)</big><ref>{{Cite journal|last=Tanaka|first=T.|last2=Ohmori|first2=M.|last3=Yasunaga|first3=S.|last4=Ohshima|first4=K.|last5=Kikuchi|first5=M.|last6=Sasazuki|first6=T.|date=1999-09|title=DNA typing of HLA class II genes (HLA‐DR, ‐DQ and ‐DP) in Japanese patients with histiocytic necrotizing lymphadenitis (Kikuchi’s disease)|url=https://onlinelibrary.wiley.com/doi/10.1034/j.1399-0039.1999.540305.x|journal=Tissue Antigens|language=en|volume=54|issue=3|pages=246–253|doi=10.1034/j.1399-0039.1999.540305.x|issn=0001-2815}}</ref> <big>in certain populations</big><big>, suggesting a genetic susceptibility</big> <big>and rare reports in siblings suggest familial susceptibility</big><big>.</big><ref>{{Cite journal|last=Isoda|first=Atsushi|last2=Tahara|first2=Kenichi|last3=Ide|first3=Munenori|date=2023-12|title=Kikuchi-Fujimoto Disease in Human Leukocyte Antigen Partially Matched Siblings: A Case Study of Familial Susceptibility|url=https://pubmed.ncbi.nlm.nih.gov/38264372|journal=Cureus|volume=15|issue=12|pages=e51010|doi=10.7759/cureus.51010|issn=2168-8184|pmc=10803893|pmid=38264372}}</ref> | ||
==Additional Information== | ==Additional Information== | ||
<big>Most published studies indicate a | <big>Most published studies indicate a reactive, immune-mediated process rather than a neoplastic one.</big><ref>{{Cite journal|last=Li|first=Elizabeth Y.|last2=Xu|first2=Jason|last3=Nelson|first3=Nya D.|last4=Teachey|first4=David T.|last5=Tan|first5=Kai|last6=Romberg|first6=Neil|last7=Behrens|first7=Ed|last8=Pillai|first8=Vinodh|date=2022-04|title=Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response|url=https://pubmed.ncbi.nlm.nih.gov/34952944|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=35|issue=4|pages=462–469|doi=10.1038/s41379-021-00992-7|issn=1530-0285|pmid=34952944}}</ref> | ||
==Links== | ==Links== | ||
<big> | <big>N/A</big> | ||
==References== | ==References== | ||